MaxCyte
Gaithersburg, MD
Platform Provider
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (5)
Quick Facts: MaxCyte
- Signal Score
- 59.0/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Gaithersburg, MD
- Modalities
- CAR-T, Cell Therapy
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
M&A activity detected (1 articles)
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
M&A activity detected (1 articles)
Capacity
58.0
1 CGT manufacturing site: Gaithersburg, MD
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Gaithersburg, MD
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press5 articles
1 CGT manufacturing site: Gaithersburg, MD
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Recent News 5 articles
Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT - MarketBeat
Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT MarketBeat
MaxCyte unveils new 96-well electroporation platform to accelerate discovery - Select Science
MaxCyte unveils new 96-well electroporation platform to accelerate discovery Select Science
New MaxCyte lab device runs 96 cell samples in a three-minute cycle - Stock Titan
New MaxCyte lab device runs 96 cell samples in a three-minute cycle Stock Titan
DC Inno - MoCo bio moves in | RapidFlight expanding - The Business Journals
DC Inno - MoCo bio moves in | RapidFlight expanding The Business Journals
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery - The Manila Times
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery The Manila Times
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: